Pharmabiz
 

Eli Lilly’s Veeva bags OPPI Sales Force Excellence Award 2013

Our Bureau, MumbaiMonday, September 30, 2013, 16:10 Hrs  [IST]

To promote excellence in pharmaceutical selling in 2012, Eli Lilly and Company - India, the leading innovation based pharmaceutical player, has won the OPPI Sales Force Excellence Award 2013 for its project Veeva which aimed at delivering unparalleled customer experience by empowering the sales force.

Lilly India recently conferred at OPPI’s AGM held in Mumbai.

Commenting on this achievement, Edgard Olaizola, managing director, Lilly India, said, “It is a great honour for Lilly India to receive this recognition for our project Veeva. At Lilly it is our mission to establish best practices for functional excellence and for creating customer delight. I would like to congratulate our sales team and the project Veeva team for this prestigious honour. This award is a testimonial to the team’s vigour and zeal and the company’s customer centricity.”

The award came in as recognition of the company’s initiative to empower its sales force for delivering unparalleled customer experience and for flawless execution of project Veeva. The project was designed to empower the sales team of approximately 300 to be self-dependant through relevant modular tool iPad & compatible CRM system Veeva.

The system helped enhance customer interaction by leveraging multimedia platform, real time reporting, well documented coaching reports and using advanced analytics to eliminate the struggle of the sales representative for doctor’s attention. The system also adequately equipped the sales representatives with micro details to monitor each SFE metric leading to efficient and effective planning. Much-coveted OPPI award was bagged by the project for achieving remarkable success and flawless execution of the project while carefully aligning the sales function with all other relevant functions and accordingly implementing Organisation Change Management (OCM).

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations.

 
[Close]